LY 341495 | LY341495 | CAS#201943-63-7 | mGlu2/3 Receptor Antagonist

MedKoo Cat#: 526740 | Name: LY-341495

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LY 341495 is a potent and selective orthosteric antagonist for the group II metabotropic glutamate receptors (mGluR2/3). Ki/IC50 values of LY-341495 are 2.3, 1.3, 173, 990, 6800, 8200 and 22000 nM for human mGlu2, mGlu3, mGlu8 , mGlu7a, mGlu1a, mGlu5a and mGlu4a receptors respectively. It is used in scientific research in several different areas, showing antidepressant effects in animal models, increasing the behavioural effects of hallucinogenic drugs in animal tests, and increasing the analgesic effects of μ-opioid agonists, as well as modulating dopamine receptor function.

Chemical Structure

LY-341495

CAS#201943-63-7

Theoretical Analysis

MedKoo Cat#: 526740

Name: LY-341495

CAS#: 201943-63-7

Chemical Formula: C20H19NO5

Exact Mass: 353.1263

Molecular Weight: 353.37

Elemental Analysis: C, 67.98; H, 5.42; N, 3.96; O, 22.64

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 370.00	2 weeks
50mg	USD 1,150.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

LY-341495; LY 341495; LY341495.

IUPAC/Chemical Name

(2S)-2-Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid

InChi Key

VLZBRVJVCCNPRJ-KPHUOKFYSA-N

InChi Code

InChI=1S/C20H19NO5/c21-20(19(24)25,15-9-13(15)18(22)23)10-14-11-5-1-3-7-16(11)26-17-8-4-2-6-12(14)17/h1-8,13-15H,9-10,21H2,(H,22,23)(H,24,25)/t13-,15-,20-/m0/s1

SMILES Code

O=C(O)[C@]([C@@H]1[C@@H](C(O)=O)C1)(N)CC2C3=C(OC4=C2C=CC=C4)C=CC=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

LY341495 is a metabotropic glutamate receptor (mGluR) antagonist with IC50s of 21 nM, 14 nM, 7.8 μM, 8.2 μM, 170 nM, 990 nM, 22 μM for mGlu2, mGlu3, mGlu1a, mGlu5a, mGlu8, mGlu7, and mGlu4 receptors, respectively.

In vitro activity:

Using membranes from cells expressing human mGlu2 and mGlu3 receptors, [3H]-LY341495 (1 nM) specific binding was > 90% of total binding. At an approximate K(D) concentration for [3H]-LY341495 binding to human mGlu2 and mGlu3 receptors (1 nM), no appreciable specific binding of [3H-]LY341495 was found in membranes of cells expressing human mGlu1a, mGlu5a, mGlu4a, mGlu6, or mGlu7a receptors. Reference: Neuropharmacology. 1999 Oct;38(10):1519-29. https://pubmed.ncbi.nlm.nih.gov/10530814/

In vivo activity:

To clarify the role of mGlu2/3 receptor antagonists in one aspect of cognition, the present study investigated the effects of a broad range of doses of the mGlu2/3 receptor antagonist LY341495 on post-training recognition memory components (storage and/or retrieval) in rats. The highest LY341495 doses administered (0.3, 1, and 3 mg/kg) disrupted performance in this recognition memory procedure in rats at all delay conditions tested, whereas administration of lower doses (0.05 and 0.1 mg/kg) did not impair recognition memory. Moreover, administration of the low LY341495 doses (0.05 and 0.1 mg/kg) counteracted the extinction of recognition memory. Reference: Behav Brain Res. 2012 May 1;230(2):374-9. https://pubmed.ncbi.nlm.nih.gov/22586715/

	Solvent	mg/mL	mM
Solubility
	DMSO	3.9	10.99

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 353.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Johnson BG, Wright RA, Arnold MB, Wheeler WJ, Ornstein PL, Schoepp DD. [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology. 1999 Oct;38(10):1519-29. doi: 10.1016/s0028-3908(99)00053-2. PMID: 10530814. 2. Fitzjohn SM, Bortolotto ZA, Palmer MJ, Doherty AJ, Ornstein PL, Schoepp DD, Kingston AE, Lodge D, Collingridge GL. The potent mGlu receptor antagonist LY341495 identifies roles for both cloned and novel mGlu receptors in hippocampal synaptic plasticity. Neuropharmacology. 1998 Dec;37(12):1445-58. doi: 10.1016/s0028-3908(98)00145-2. PMID: 9886667. 3. Pitsikas N, Kaffe E, Markou A. The metabotropic glutamate 2/3 receptor antagonist LY341495 differentially affects recognition memory in rats. Behav Brain Res. 2012 May 1;230(2):374-9. doi: 10.1016/j.bbr.2012.02.027. PMID: 22586715; PMCID: PMC3705739. 4. Linden AM, Johnson BG, Trokovic N, Korpi ER, Schoepp DD. Use of MGLUR2 and MGLUR3 knockout mice to explore in vivo receptor specificity of the MGLUR2/3 selective antagonist LY341495. Neuropharmacology. 2009 Aug;57(2):172-82. doi: 10.1016/j.neuropharm.2009.05.002. Epub 2009 May 27. PMID: 19477188.

In vitro protocol:

In vivo protocol:

1. Pitsikas N, Kaffe E, Markou A. The metabotropic glutamate 2/3 receptor antagonist LY341495 differentially affects recognition memory in rats. Behav Brain Res. 2012 May 1;230(2):374-9. doi: 10.1016/j.bbr.2012.02.027. PMID: 22586715; PMCID: PMC3705739. 2. Linden AM, Johnson BG, Trokovic N, Korpi ER, Schoepp DD. Use of MGLUR2 and MGLUR3 knockout mice to explore in vivo receptor specificity of the MGLUR2/3 selective antagonist LY341495. Neuropharmacology. 2009 Aug;57(2):172-82. doi: 10.1016/j.neuropharm.2009.05.002. Epub 2009 May 27. PMID: 19477188.

1: Podkowa K, Pochwat B, Brański P, Pilc A, Pałucha-Poniewiera A. Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats. Psychopharmacology (Berl). 2016 Aug;233(15-16):2901-14. doi: 10.1007/s00213-016-4325-7. Epub 2016 Jun 11. PubMed PMID: 27286960. 2: Witkin JM, Monn JA, Schoepp DD, Li X, Overshiner C, Mitchell SN, Carter G, Johnson B, Rasmussen K, Rorick-Kehn LM. The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits. J Pharmacol Exp Ther. 2016 Jul;358(1):71-82. doi: 10.1124/jpet.116.233627. Epub 2016 May 12. PubMed PMID: 27189960. 3: McOmish CE, Pavey G, Gibbons A, Hopper S, Udawela M, Scarr E, Dean B. Lower [3H]LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia. J Affect Disord. 2016 Jan 15;190:241-8. doi: 10.1016/j.jad.2015.10.004. Epub 2015 Oct 23. PubMed PMID: 26521087. 4: Koike H, Chaki S. Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav Brain Res. 2014 Sep 1;271:111-5. doi: 10.1016/j.bbr.2014.05.065. Epub 2014 Jun 5. PubMed PMID: 24909673. 5: Fukumoto K, Iijima M, Chaki S. Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test. Psychopharmacology (Berl). 2014 Jun;231(11):2291-8. doi: 10.1007/s00213-013-3378-0. Epub 2014 Jan 9. PubMed PMID: 24402133. 6: Yelskaya Z, Carrillo V, Dubisz E, Gulzar H, Morgan D, Mahajan SS. Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and Iressa. PLoS One. 2013 May 27;8(5):e64588. doi: 10.1371/journal.pone.0064588. Print 2013. PubMed PMID: 23724064; PubMed Central PMCID: PMC3664620. 7: Koike H, Iijima M, Chaki S. Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats. Pharmacol Biochem Behav. 2013 Jun;107:20-3. doi: 10.1016/j.pbb.2013.03.017. Epub 2013 Apr 9. PubMed PMID: 23578563. 8: Moreno JL, Holloway T, Rayannavar V, Sealfon SC, González-Maeso J. Chronic treatment with LY341495 decreases 5-HT(2A) receptor binding and hallucinogenic effects of LSD in mice. Neurosci Lett. 2013 Mar 1;536:69-73. doi: 10.1016/j.neulet.2012.12.053. Epub 2013 Jan 16. PubMed PMID: 23333599; PubMed Central PMCID: PMC3578056. 9: Pitsikas N, Kaffe E, Markou A. The metabotropic glutamate 2/3 receptor antagonist LY341495 differentially affects recognition memory in rats. Behav Brain Res. 2012 May 1;230(2):374-9. PubMed PMID: 22586715; PubMed Central PMCID: PMC3705739. 10: Sutton LP, Rushlow WJ. Regulation of Akt and Wnt signaling by the group II metabotropic glutamate receptor antagonist LY341495 and agonist LY379268. J Neurochem. 2011 Jun;117(6):973-83. doi: 10.1111/j.1471-4159.2011.07268.x. Epub 2011 May 13. PubMed PMID: 21477044. 11: Linden AM, Johnson BG, Trokovic N, Korpi ER, Schoepp DD. Use of MGLUR2 and MGLUR3 knockout mice to explore in vivo receptor specificity of the MGLUR2/3 selective antagonist LY341495. Neuropharmacology. 2009 Aug;57(2):172-82. doi: 10.1016/j.neuropharm.2009.05.002. Epub 2009 May 27. PubMed PMID: 19477188. 12: Semenova S, Markou A. The effects of the mGluR5 antagonist MPEP and the mGluR2/3 antagonist LY341495 on rats' performance in the 5-choice serial reaction time task. Neuropharmacology. 2007 Mar;52(3):863-72. Epub 2006 Nov 28. PubMed PMID: 17126859; PubMed Central PMCID: PMC1847349. 13: Liechti ME, Markou A. Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats. Eur J Pharmacol. 2007 Jan 12;554(2-3):164-74. Epub 2006 Oct 17. PubMed PMID: 17113075; PubMed Central PMCID: PMC1803080. 14: Ngomba RT, Biagioni F, Casciato S, Willems-van Bree E, Battaglia G, Bruno V, Nicoletti F, van Luijtelaar EL. The preferential mGlu2/3 receptor antagonist, LY341495, reduces the frequency of spike-wave discharges in the WAG/Rij rat model of absence epilepsy. Neuropharmacology. 2005;49 Suppl 1:89-103. PubMed PMID: 16043198. 15: Linden AM, Bergeron M, Schoepp DD. Comparison of c-Fos induction in the brain by the mGlu2/3 receptor antagonist LY341495 and agonist LY354740: evidence for widespread endogenous tone at brain mGlu2/3 receptors in vivo. Neuropharmacology. 2005;49 Suppl 1:120-34. PubMed PMID: 16023151. 16: Feinberg I, Schoepp DD, Hsieh KC, Darchia N, Campbell IG. The metabotropic glutamate (mGLU)2/3 receptor antagonist LY341495 [2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid] stimulates waking and fast electroencephalogram power and blocks the effects of the mGLU2/3 receptor agonist ly379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] in rats. J Pharmacol Exp Ther. 2005 Feb;312(2):826-33. Epub 2004 Sep 21. PubMed PMID: 15383637. 17: Rasmussen K, Hsu MA, Vandergriff J. The selective mGlu2/3 receptor antagonist LY341495 exacerbates behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons. Neuropharmacology. 2004 Apr;46(5):620-8. PubMed PMID: 14996539. 18: O'Neill MF, Heron-Maxwell C, Conway MW, Monn JA, Ornstein P. Group II metabotropic glutamate receptor antagonists LY341495 and LY366457 increase locomotor activity in mice. Neuropharmacology. 2003 Oct;45(5):565-74. PubMed PMID: 12941370. 19: Howson PA, Jane DE. Actions of LY341495 on metabotropic glutamate receptor-mediated responses in the neonatal rat spinal cord. Br J Pharmacol. 2003 May;139(1):147-55. PubMed PMID: 12746233; PubMed Central PMCID: PMC1573828. 20: Waterhouse RN, Schmidt ME, Sultana A, Schoepp DD, Wheeler WJ, Mozley PD, Laruelle M. Evaluation of [3H]LY341495 for labeling group II metabotropic glutamate receptors in vivo. Nucl Med Biol. 2003 Feb;30(2):187-90. PubMed PMID: 12623118.